Vaccine Info

UB-311 Alzheimer's Vaccine


UB-311 is fully synthetic and employs the UBITh platform technologies to target aggregated forms of beta-amyloid. 


UB-311 is indicated for the treatment of Alzheimer's disease.


UB-311 is administered as an intramuscular injection

Clinical Trial NCT03531710: An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)

  • The top-line Phase 2a data met the primary aims of safety and immunogenicity with a 96% response rate. All secondary endpoints - including Amyloid PET burden, CDR-SB, ADCS-ADL, ADAS-Cog and MMSE - pointed directionally in favor of UB-311, though not statistically significant with the study sample size.